A
Ajay Nirula
Researcher at Amgen
Publications - 34
Citations - 2404
Ajay Nirula is an academic researcher from Amgen. The author has contributed to research in topics: Brodalumab & Medicine. The author has an hindex of 14, co-authored 26 publications receiving 1849 citations. Previous affiliations of Ajay Nirula include Biogen Idec & Eli Lilly and Company.
Papers
More filters
Journal ArticleDOI
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl,Bruce Strober,Alan Menter,Kenneth B. Gordon,Jolanta Weglowska,Lluís Puig,Kim A. Papp,Lynda Spelman,Darryl Toth,Francisco A. Kerdel,April W. Armstrong,Georg Stingl,Alexa B. Kimball,Hervé Bachelez,Jashin J. Wu,Jeffrey J. Crowley,Richard G. Langley,Tomasz Blicharski,Carle Paul,Jean-Philippe Lacour,Stephen K. Tyring,Leon H Kircik,Sergio Chimenti,Kristina Callis Duffin,Jerry Bagel,John Koo,Gary Aras,Joanne Li,Wenjie Song,Cassandra E Milmont,Yifei Shi,Ngozi Erondu,Paul Klekotka,Brian L Kotzin,Ajay Nirula +34 more
TL;DR: Bdalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis, and was found to be superior to placebo at week 12 with respect to a 100% reduction in PASI score (PASI 100).
Journal ArticleDOI
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†
Kim A. Papp,Kristian Reich,Carle Paul,Andrew Blauvelt,W. Baran,Chantal Bolduc,Darryl Toth,Richard G. Langley,J. Cather,Alice B. Gottlieb,Diamant Thaçi,James G. Krueger,Chris B. Russell,Cassandra E Milmont,Joanne Li,Paul Klekotka,Gregory Kricorian,Ajay Nirula +17 more
TL;DR: The interleukin‐17 cytokine family plays a central role in psoriasis pathogenesis and is associated with atypical immune responses and central nervous system disorders.
Journal ArticleDOI
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Philip J. Mease,Mark C. Genovese,Maria Greenwald,Christopher T. Ritchlin,André D. Beaulieu,A. A. Deodhar,Richard Newmark,Jing Yuan Feng,Ngozi Erondu,Ajay Nirula +9 more
TL;DR: Bdalumab significantly improved response rates among patients with psoriatic arthritis; responses were sustained through week 52 and larger studies of longer duration are necessary to assess adverse events.
Journal ArticleDOI
What is IgG4? A review of the biology of a unique immunoglobulin subtype.
TL;DR: IgG4 is a unique antibody biologically and structurally that undergoes ‘half-antibody exchange’ in vivo, resulting in recombined antibodies composed of two different binding specificities.
Journal ArticleDOI
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial
Myron S. Cohen,Ajay Nirula,Mark J. Mulligan,Richard M. Novak,Mary A. Marovich,Catherine Yen,Alexander Stemer,Stockton Mayer,David A. Wohl,Blair Brengle,Brian T. Montague,Ian Frank,Russell J. McCulloh,Carl J. Fichtenbaum,Brad Lipson,Nashwa Gabra,Julio Ramirez,Christine Thai,Wairimu Chege,Margarita M. Gomez Lorenzo,Nirupama Sista,Jennifer Farrior,Meredith E. Clement,Elizabeth R. Brown,Kenneth L. Custer,Jacob Van Naarden,Andrew C. Adams,Andrew E. Schade,Matan C. Dabora,Jack Knorr,Karen L. Price,Janelle Sabo,Jay Tuttle,Paul A. Klekotka,Lei Shen,Daniel Skovronsky +35 more
TL;DR: Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may provide rapid protection from SARS infection and COVID-19.